ADPKD, Tolvaptan, and Nephrolithiasis Risk

Ewout J Hoorn; Robert Zietse

doi:10.2215/CJN.07610520

ADPKD, Tolvaptan, and Nephrolithiasis Risk

Clin J Am Soc Nephrol. 2020 Jul 1;15(7):923-925. doi: 10.2215/CJN.07610520. Epub 2020 Jun 11.

Authors

Ewout J Hoorn¹, Robert Zietse

Affiliation

¹ Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.

No abstract available

Keywords: Autosomal Dominant; Kidney Calculi; Polycystic Kidney; Tolvaptan; calcium; cyclic AMP; cystic kidney; hypercalciuria; kidney stones; kidney tubule; polycystic kidney disease; risk factors.

Publication types

Editorial
Comment

MeSH terms

Antidiuretic Hormone Receptor Antagonists / adverse effects
Humans
Kidney Calculi*
Polycystic Kidney, Autosomal Dominant* / drug therapy
Tolvaptan / adverse effects

Substances

Antidiuretic Hormone Receptor Antagonists
Tolvaptan